In addition, it appears that the anti-lymphoma effects of IL-21 are dependent on a mechanism involving the IL-21-activated STAT3 upregulation of c-Myc, in which c-Myc is a highly prognostic marker in DLBCL (17,18). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.